These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28935561)

  • 1. Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine.
    Maier SB; Huang X; Massad E; Amaku M; Burattini MN; Greenhalgh D
    Math Biosci; 2017 Dec; 294():15-32. PubMed ID: 28935561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Optimal Age of Vaccination Against Dengue with an Age-Dependent Biting Rate with Application to Brazil.
    Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D
    Bull Math Biol; 2020 Jan; 82(1):12. PubMed ID: 31933012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimal age of vaccination against dengue in Brazil based on serotype-specific forces of infection derived from serological data.
    Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D
    Math Med Biol; 2021 Mar; 38(1):1-27. PubMed ID: 32671383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A conceptual model for optimizing vaccine coverage to reduce vector-borne infections in the presence of antibody-dependent enhancement.
    Tang B; Huo X; Xiao Y; Ruan S; Wu J
    Theor Biol Med Model; 2018 Sep; 15(1):13. PubMed ID: 30173664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneities in dengue spatial-temporal transmission in Brazilian cities and its influence on the optimal age of vaccination.
    Cardim LL; Pinho STR; Teixeira MG; Costa MCN; Esteva ML; Ferreira CP
    BMC Public Health; 2019 Feb; 19(1):155. PubMed ID: 30727988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing a vaccination strategy against dengue.
    Amaku M; Coudeville L; Massad E
    Rev Inst Med Trop Sao Paulo; 2012 Oct; 54 Suppl 18():S18-21. PubMed ID: 23011455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tetravalent dengue vaccination with screening, ADE, and altered infectivity on single-serotype dengue and Zika transmission.
    Kribs C; Greenhalgh D
    J Math Biol; 2023 Apr; 86(5):85. PubMed ID: 37119296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Impact of Vaccination on the Dynamics of Dengue Infections.
    Knipl D; Moghadas SM
    Bull Math Biol; 2015 Dec; 77(12):2212-30. PubMed ID: 26585748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
    Shim E
    Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological view of vaccination described by mathematical modellings: from rubella to dengue vaccines.
    Yang MH; Freitas ARR
    Math Biosci Eng; 2019 Apr; 16(4):3195-3214. PubMed ID: 31499609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine.
    Coudeville L; Baurin N; L'Azou M; Guy B
    Vaccine; 2016 Dec; 34(50):6426-6435. PubMed ID: 27601343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical assessment of the role of Dengvaxia vaccine on the transmission dynamics of dengue serotypes.
    Iboi EA; Gumel AB
    Math Biosci; 2018 Oct; 304():25-47. PubMed ID: 30025788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dengue vaccination strategies of seropositive individuals.
    Shim E
    Math Biosci Eng; 2019 Feb; 16(3):1171-1189. PubMed ID: 30947414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies.
    Coudeville L; Baurin N; Vergu E
    Vaccine; 2016 Dec; 34(50):6417-6425. PubMed ID: 26614588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue vaccines: what we know, what has been done, but what does the future hold?
    Abrão EP; Espósito DL; Lauretti F; da Fonseca BA
    Rev Saude Publica; 2015; 49():60. PubMed ID: 26398877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.